Predisposition to Apoptosis in Hepatocellular Carcinoma: From Mechanistic Insights to Therapeutic Strategies
暂无分享,去创建一个
[1] Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. , 2020, CA: a cancer journal for clinicians.
[2] Gregory J. Gores,et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management , 2019, Nature Reviews Gastroenterology & Hepatology.
[3] J. Marquardt,et al. Context-Dependent Role of NF-κB Signaling in Primary Liver Cancer—from Tumor Development to Therapeutic Implications , 2019, Cancers.
[4] Wei Li,et al. Global liver disease burdens and research trends: Analysis from a Chinese perspective. , 2019, Journal of hepatology.
[5] M. Karin,et al. The Fire within: Cell-Autonomous Mechanisms in Inflammation-Driven Cancer. , 2019, Cancer cell.
[6] Li Jin,et al. The trends in incidence of primary liver cancer caused by specific etiologies: Results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention. , 2019, Journal of hepatology.
[7] Elizabeth J. Osterlund,et al. Bim escapes displacement by BH3-mimetic anti-cancer drugs by double-bolt locking both Bcl-XL and Bcl-2 , 2019, eLife.
[8] D. Pollyea,et al. Why are hypomethylating agents or low-dose cytarabine and venetoclax so effective? , 2019, Current opinion in hematology.
[9] A. Vogel,et al. The Changing Landscape of Systemic Treatment of Advanced Hepatocellular Carcinoma: New Targeted Agents and Immunotherapies , 2019, Targeted Oncology.
[10] T. Kipps,et al. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] E. Seki,et al. Inflammation and Liver Cancer: Molecular Mechanisms and Therapeutic Targets , 2019, Seminars in Liver Disease.
[12] A. Letai,et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. , 2019, Blood.
[13] Y. Funahashi,et al. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1‐6 hepatocellular carcinoma model , 2018, Cancer science.
[14] Austin E. Gillen,et al. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia , 2018, Nature Medicine.
[15] O. Ohara,et al. Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC , 2018, Cell.
[16] J. Fernandez-Checa,et al. Mitochondrial Oxidative Stress and Antioxidants Balance in Fatty Liver Disease , 2018, Hepatology communications.
[17] T. Luedde,et al. Apoptosis and necroptosis in the liver: a matter of life and death , 2018, Nature Reviews Gastroenterology & Hepatology.
[18] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[19] G. Gordon,et al. Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] M. Kudo,et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial , 2018, The Lancet.
[21] Marco Montillo,et al. Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia , 2018, The New England journal of medicine.
[22] S. Lipton,et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018 , 2018, Cell Death & Differentiation.
[23] G. Ghanem,et al. PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies , 2017, Cancers.
[24] K. Döhner,et al. Mitochondrial BAX Determines the Predisposition to Apoptosis in Human AML , 2017, Clinical Cancer Research.
[25] S. Thorgeirsson,et al. Adverse genomic alterations and stemness features are induced by field cancerization in the microenvironment of hepatocellular carcinomas , 2017, Oncotarget.
[26] T. Luedde,et al. RIPK1 Suppresses a TRAF2-Dependent Pathway to Liver Cancer. , 2017, Cancer cell.
[27] E. Pérez-Payá,et al. Bax transmembrane domain interacts with prosurvival Bcl-2 proteins in biological membranes , 2016, Proceedings of the National Academy of Sciences.
[28] A. Canbay,et al. Cell death mechanisms in human chronic liver diseases: a far cry from clinical applicability. , 2016, Clinical science.
[29] B. Zee,et al. Randomized Phase II Study of the X-linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) , 2016, American journal of clinical oncology.
[30] T. Rodt,et al. Serum Cell Death Biomarker Mirrors Liver Cancer Regression after Transarterial Chemoembolisation , 2016, Zeitschrift für Gastroenterologie.
[31] S. R. Kopalli,et al. Necroptosis inhibitors as therapeutic targets in inflammation mediated disorders - a review of the current literature and patents , 2016, Expert opinion on therapeutic patents.
[32] M. Omary,et al. Keratins: Biomarkers and modulators of apoptotic and necrotic cell death in the liver , 2016, Hepatology.
[33] Ji Luo,et al. NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis , 2016, Nature.
[34] I. Fabregat,et al. Apoptosis in liver carcinogenesis and chemotherapy. , 2015, Hepatic oncology.
[35] S. Thorgeirsson,et al. Functional and genetic deconstruction of the cellular origin in liver cancer , 2015, Nature Reviews Cancer.
[36] M. Manns,et al. The BH3‐only protein BID impairs the p38‐mediated stress response and promotes hepatocarcinogenesis during chronic liver injury in mice , 2015, Hepatology.
[37] A. Wree,et al. Hepatocyte-specific Bid depletion reduces tumor development by suppressing inflammation-related compensatory proliferation , 2015, Cell Death and Differentiation.
[38] L. Walensky,et al. Inhibition of Pro-apoptotic BAX by a noncanonical interaction mechanism. , 2015, Molecular cell.
[39] Karen Blyth,et al. Limited Mitochondrial Permeabilization Causes DNA Damage and Genomic Instability in the Absence of Cell Death , 2015, Molecular cell.
[40] S. Frank,et al. Differential retrotranslocation of mitochondrial Bax and Bak , 2015, The EMBO journal.
[41] J. Zucman‐Rossi,et al. Molecular Profiling of Liver Tumors: Classification and Clinical Translation for Decision Making , 2014, Seminars in Liver Disease.
[42] M. Karin,et al. ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development. , 2014, Cancer cell.
[43] J. Trojan,et al. Diagnostic and prognostic significance of cell death and macrophage activation markers in patients with hepatocellular carcinoma. , 2013, Journal of hepatology.
[44] G. Giovinazzo,et al. Myc-driven endogenous cell competition in the early mammalian embryo , 2013, Nature.
[45] S. Friedman,et al. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. , 2013, Gastroenterology.
[46] E. Albano,et al. NF-κB1 deficiency stimulates the progression of non-alcoholic steatohepatitis (NASH) in mice by promoting NKT-cell-mediated responses. , 2013, Clinical science.
[47] Z. Çakır,et al. The C-terminal helix of Bcl-xL mediates Bax retrotranslocation from the mitochondria , 2012, Cell Death and Differentiation.
[48] A. Letai,et al. Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML , 2012, Cell.
[49] H. El‐Serag,et al. Epidemiology of viral hepatitis and hepatocellular carcinoma. , 2012, Gastroenterology.
[50] I. Fabregat,et al. Sorafenib sensitizes hepatocellular carcinoma cells to physiological apoptotic stimuli , 2012, Journal of cellular physiology.
[51] A. Letai,et al. Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy , 2011, Science.
[52] Nico Tjandra,et al. Bcl-xL Retrotranslocates Bax from the Mitochondria into the Cytosol , 2011, Cell.
[53] T. Luedde,et al. NF-κB in the liver—linking injury, fibrosis and hepatocellular carcinoma , 2011, Nature Reviews Gastroenterology &Hepatology.
[54] S. Thorgeirsson,et al. Definition of ubiquitination modulator COP1 as a novel therapeutic target in human hepatocellular carcinoma. , 2010, Cancer research.
[55] A. Letai,et al. Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4+ CD8+ thymocytes , 2010, Proceedings of the National Academy of Sciences.
[56] Thomas J. Fuchs,et al. TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to liver cancer. , 2010, Cancer cell.
[57] Derek W. Yecies,et al. MCL-1–dependent leukemia cells are more sensitive to chemotherapy than BCL-2–dependent counterparts , 2009, The Journal of cell biology.
[58] R. Hotchkiss,et al. Cell death. , 2009, The New England journal of medicine.
[59] T. Luedde,et al. p38α MAPK inhibits JNK activation and collaborates with IκB kinase 2 to prevent endotoxin‐induced liver failure , 2008, EMBO reports.
[60] N. Tjandra,et al. BAX Activation is Initiated at a Novel Interaction Site , 2008, Nature.
[61] A. Elsharkawy,et al. Nuclear factor‐κB and the hepatic inflammation‐fibrosis‐cancer axis , 2007 .
[62] P. Ekert,et al. Programmed Anuclear Cell Death Delimits Platelet Life Span , 2007, Cell.
[63] Ronald A. DePinho,et al. Hepatocellular carcinoma pathogenesis: from genes to environment , 2006, Nature Reviews Cancer.
[64] S. Armstrong,et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. , 2006, Cancer cell.
[65] N. Chen,et al. First-in-class pan caspase inhibitor developed for the treatment of liver disease. , 2005, Journal of medicinal chemistry.
[66] S. Thorgeirsson,et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling , 2004, Hepatology.
[67] M. Karin,et al. Inhibition of JNK activation through NF-κB target genes , 2001, Nature.
[68] H. Pahl. Activators and target genes of Rel/NF-κB transcription factors , 1999, Oncogene.
[69] B. Corfe,et al. Cell Damage-induced Conformational Changes of the Pro-Apoptotic Protein Bak In Vivo Precede the Onset of Apoptosis , 1999, The Journal of cell biology.
[70] Jean-Claude Martinou,et al. Bax-induced Cytochrome C Release from Mitochondria Is Independent of the Permeability Transition Pore but Highly Dependent on Mg2+ Ions , 1998, The Journal of cell biology.
[71] Junying Yuan,et al. Cleavage of BID by Caspase 8 Mediates the Mitochondrial Damage in the Fas Pathway of Apoptosis , 1998, Cell.
[72] Y. Hsu,et al. Bax in Murine Thymus Is a Soluble Monomeric Protein That Displays Differential Detergent-induced Conformations* , 1998, The Journal of Biological Chemistry.
[73] Z. Oltvai,et al. Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[74] S. Korsmeyer,et al. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death , 1993, Cell.
[75] J. Sulston,et al. Post-embryonic cell lineages of the nematode, Caenorhabditis elegans. , 1977, Developmental biology.
[76] J. Shields,et al. Genes or environment , 1976, Nature.
[77] Samir Guglani. Death , 1890, The Lancet.
[78] M. Pasparakis,et al. RIP Kinases in Liver Cell Death, Inflammation and Cancer. , 2019, Trends in molecular medicine.
[79] P. Galle,et al. Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): an emerging field for advanced technologies. , 2012, Journal of hepatology.
[80] A. Strasser,et al. The BCL-2 protein family: opposing activities that mediate cell death , 2008, Nature Reviews Molecular Cell Biology.
[81] J. Risk,et al. Bim, Bad and Bmf: intrinsically unstructured BH3-only proteins that undergo a localized conformational change upon binding to prosurvival Bcl-2 targets , 2007, Cell Death and Differentiation.
[82] J Salvage,et al. A matter of life and death. , 1981, Nursing times.